To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Safety Alert: Patients Taking Arava (Leflunomide) for Rheumatoid Arthritis Asked to Take Precautions Against Liver Injury URL: http://www.pslgroup.com/dg/1FA542.htm Doctor's Guide May 8, 2001
LAVAL, QC -- May 8, 2001 -- Aventis Pharma Inc. announced today that it is issuing a letter to healthcare professionals regarding reports of liver injury in patients taking its drug leflunomide, sold under the brand name Aravaź (leflunomide). Arava is used to treat patients with active rheumatoid arthritis. Patients with rheumatoid arthritis often have other serious medical conditions and receive several drugs in their treatment regimen that could be toxic to the liver. Therefore, it is difficult to identify definitively a specific cause for severe liver injury. "Many other factors could be involved in these cases, but we cannot completely exclude a causal relationship to leflunomide at this time," says Dr. Jean Bourgouin, Vice-President of Scientific Affairs at Aventis Pharma. "That's why we urge that patients experiencing symptoms such as nausea, vomiting, stomach pain or swelling, jaundice, dark urine or unusual tiredness report these to their doctor at once." In view of this new information, Aventis has posted its product and patient monograph on its Web site at www.aventispharma.ca. Blood tests may show an increase in some liver enzymes, which in very rare cases may develop into serious conditions such as hepatitis and liver failure. Isolated cases with fatal outcomes have been observed. Arava has been on the market in Canada since March 2000 and, when used according to product labeling and under physician supervision, is a safe and efficacious drug. SOURCE: Aventis Pharma Inc. Related Link: Aventis Pharma Inc.. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.